AI Biologist - Cell Therapy Discovery
LatchBio
Summary
Latch builds rigorous scientific benchmarks for AI agents across biology, working with frontier labs and pharma to measure whether agents can handle real biological workflows. We're seeking an AI Biologist to join our Cell Therapy Discovery team, pushing what AI can achieve in engineered cell design.
Job description
About the Role
You will be the scientific authority on ground truth, testing whether agents can reason like an expert cell therapy scientist. You will build the tasks and datasets behind our benchmarks across CAR, TCR, and other engineered cell formats, from antigen selection to candidate nomination.
Build the task
- Write gold-standard answers with the rationale an experienced cell therapy scientist would defend.
- Design scenarios across the discovery arc: antigen prioritization, receptor and construct design, phenotype, potency and killing, cytokine profiling, exhaustion and persistence, on-target off-tumor triage.
- Curate datasets from real programs: multiparameter flow and spectral panels, luciferase, impedance, and imaging cytotoxicity across E:T ratios, cytokine multiplex, repeat-stimulation and serial-killing assays, inhibitory receptor panels, memory phenotype distributions, normal-tissue antigen expression.
- Build analysis pipelines in Python where useful, with tolerances that hold across donors, runs, and readout platforms.
Set the hard calls
- Catch the artifact: construct surface expression differences, E:T saturation erasing potency differences, viability readouts confounded by dead effectors, activation-induced cell death, lysis normalization, donor variation, spillover error.
- Separate activation from exhaustion: distinguish transient activation markers from stable exhaustion requiring sustained stimulation and functional loss.
- Recognize tonic signaling: antigen-independent activation from scFv instability, self-aggregation, or domain choice.
- Adjudicate conflicts: strong short-term killing vs poor persistence, low cytokine output as design choice or failing product, and name the experiment that settles it.
- Weigh tradeoffs: potency vs exhaustion, cytokine output vs toxicity risk, affinity vs on-target off-tumor selectivity, expansion gain vs memory phenotype.
Judge the agent
Interrogate reasoning step by step, challenge conclusions that would not survive a project review, pinpoint where agents go wrong, and score confidence, rewarding explicit uncertainty over overconfident calls on ambiguous data.
Requirements
- PhD in immunology, cell biology, bioengineering, or a related field; MS with equivalent hands-on program experience also qualifies
- 2 to 6 years hands-on in cell therapy at a biotech or pharma, with own analysis work in the last two years
- Personally generated or analyzed data that decided which target or construct advanced
- Direct experience with at least one of: CAR or TCR construct design, multiparameter flow panel design and analysis, cytotoxicity and co-culture assays, cytokine profiling, or exhaustion and persistence characterization
- Strong experimental design, quantitative analysis, and statistics
- Daily use of Claude, Cursor, or similar AI tools with judgment to spot unsound model reasoning
- Bonus: Python or R for own analyses
- Bonus: allogeneic or gene-edited cell therapy, NK or Treg formats, or in vivo CAR
Benefits
- Health, Dental & Vision Insurance
- 401(k)
- 15 Days PTO
- Equity
- Sign-on Bonus
- H-1B, O-1, TN Sponsorship
- STEM OPT Support
Company overview
LatchBio is a San Francisco-based cloud platform that provides comprehensive data infrastructure and analysis tools for biotechnology research. Founded in 2021, the company offers a unified data platform designed to connect bench scientists, computational scientists, IT teams, and R&D leadership into a cohesive framework. Their platform enables scientists to store, transform, and visualize bioinformatics data, making data analysis faster, more accessible, and cost-effective. LatchBio's solution includes workflow orchestration, scalable cloud computing resources, data storage, and interactive visualization tools specifically tailored for biological data analysis. The company serves hundreds of biotech companies and research organizations, helping them accelerate R&D milestones by eliminating infrastructure complexities. With backing from prominent investors including Lux Capital and Coatue, LatchBio has raised significant funding to develop its platform that supports various omics technologies including NGS, spatial transcriptomics, and single-cell analysis.